GRAVITINCT05197049
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 54 versions: 39 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion moved earlier from Oct 30, 2028 to Mar 27, 2028
- Site details revised at 7 of 345 sites
- Notable Eligibility criteria expanded, about 6 words
- Secondary endpoints: details revised at 6 of 6 entries
- Study sites revised (345)
- Publications: details revised at 1 of 1 entry
- Minor Study sites revised (345)v52
- Minor Study sites revised (345)v51
- Minor Site details revised at 1 of 345 sitesv49
Show 34 earlier versionsHide 34 earlier versions
- Minor Study sites: 344 to 345v47
- Minor Study sites: 343 to 344v46
- Minor Study sites: 344 to 343v45
- Minor Site details revised at 1 of 344 sitesv44
- Minor Study completion date: Mar 27, 2028 to Oct 30, 2028v41
- Minor Study sites revised (344)v40
- Minor Study sites: 341 to 344v38
Notable Results first posted: Feb 21, 2025v32 Show 4 more changesShow less
- Primary endpoints revised (2)
- Study sites: 342 to 341
- Study completion date: Mar 31, 2025 to Mar 27, 2028
- Secondary endpoints: 4 to 6
- Minor Secondary endpoints: details revised at 1 of 4 entries
- Study description shortened, about 95 words
- Study sites revised (342)
- Minor Study sites revised (342)v30
- Minor Site details revised at 2 of 342 sitesv29
- Minor Study sites revised (342)v28
- Minor Study sites revised (342)v27
- Minor Study sites revised (342)v26
- Minor Study sites revised (342)v25
- Minor Study completion date: Jun 30, 2025 to Mar 31, 2025
- Study sites revised (342)
- Minor Study sites revised (342)v23
- Minor Study sites revised (342)v22
- Minor Study sites revised (342)v21
- Minor Study sites: 341 to 342v20
- Minor Study sites revised (341)v19
- Minor Study sites: 342 to 341
- Study completion date: Aug 13, 2025 to Jun 30, 2025
- Minor Study sites: 341 to 342
- Study completion date: Sep 9, 2025 to Aug 13, 2025
- Minor Study sites revised (341)v16
- Minor Primary completion date: Feb 27, 2023 to Jul 4, 2023
- Study completion date: Aug 14, 2025 to Sep 9, 2025
- Minor Study sites revised (341)v13
- Minor Study sites revised (341)v12
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 318 to confirmed 350
- Study sites revised (341)
- Minor Study sites: 530 to 341
- Study completion date: Aug 13, 2025 to Aug 14, 2025
- Minor Study sites: 537 to 530
- Primary completion date changed from estimate of Jul 6, 2023 to Feb 27, 2023
- Minor Study sites: 532 to 537
- Study completion date: Feb 10, 2025 to Aug 13, 2025
- Minor Study sites: 500 to 532v7
- Minor Study sites: 384 to 500v6
- Minor Study sites: 327 to 384v5
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
Participants will receive placebo injection subcutaneously.
Drugs: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Sites
345 sites in 27 countries
United States 77, Poland 44, Japan 42, Brazil 28, China 26, South Korea 18, Germany 13, France 11, Hungary 10, Turkey (Türkiye) 8, Spain 7, Bosnia and Herzegovina 6, Jordan 6, Belgium 5, Czechia 5, Israel 5, Malaysia 5, Taiwan 5, Croatia 4, Italy 4, Netherlands 3, Slovakia 3, Australia 2, Canada 2, Denmark 2, Lithuania 2, New Zealand 2